A [Glyco] biomarker that predicts failure to standard therapy in ulcerative colitis patients

Journal of Crohn's and Colitis

Volumn 13, Issue 1, 2019, Pages 39-49

  Pereira, Márcia S ^a,b   Maia, Luís ^c   Azevedo, Luís F ^a   Campos, Sara ^a   Carvalho, Sandra ^a,b   Dias, Ana M ^a,b   Albergaria, André ^a,b,d   Lima, Jorge ^a,b,d   Marcos Pinto, Ricardo ^a,c   Lago, Paula ^c   Pinho, Salomé S ^a,b,d  

^a UNIVERSITY OF PORTO   (Portugal)

^b UNIVERSITY OF PORTO   (Portugal)

^c Centro Hospitalar Universitario do Porto   (Portugal)

^d University of Porto   (Portugal)

Author keywords

biomarker; glycosylation; Ulcerative colitis

Indexed keywords

C REACTIVE PROTEIN; GLYCOPEPTIDASE; BIOLOGICAL MARKER; CORTICOSTEROID; IMMUNOSUPPRESSIVE AGENT; MESALAZINE; NONSTEROID ANTIINFLAMMATORY AGENT; POLYSACCHARIDE;

ADULT; ARTICLE; COHORT ANALYSIS; COLON BIOPSY; CONTROLLED STUDY; CORRELATIONAL STUDY; DISEASE COURSE; FEMALE; HUMAN; HUMAN TISSUE; INDEPENDENT VARIABLE; MAJOR CLINICAL STUDY; MALE; PREDICTION; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; ULCERATIVE COLITIS; ADOLESCENT; AGED; BLOOD; COMBINATION DRUG THERAPY; INTESTINE MUCOSA; METABOLISM; MIDDLE AGED; PREDICTIVE VALUE; RECEIVER OPERATING CHARACTERISTIC; SEVERITY OF ILLNESS INDEX; TREATMENT FAILURE; YOUNG ADULT;

ADOLESCENT; ADRENAL CORTEX HORMONES; ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BIOMARKERS; C-REACTIVE PROTEIN; COLITIS, ULCERATIVE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTESTINAL MUCOSA; MALE; MESALAMINE; MIDDLE AGED; POLYSACCHARIDES; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; ROC CURVE; SEVERITY OF ILLNESS INDEX; TREATMENT FAILURE; YOUNG ADULT;

EID: 85057358772     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1093/ecco-jcc/jjy139     Document Type: Article

References (28)

1. Ordas I, Eckmann L, Talamini M, Baumgart DC, Sandborn WJ. Ulcerative colitis. Lancet 2012; 380:1606-19.
2. Baumgart DC, Sandborn WJ. Crohn's disease. Lancet 2012; 380:1590-605.
3. Molodecky NA, Soon IS, Rabi DM, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 2012; 142:46-54.e42; quiz e30.
4. Kaplan GG. The global burden of IBD: From 2015 to 2025. Nat Rev Gastroenterol Hepatol 2015; 12:720-7.
5. Lonnfors S, Vermeire S, Greco M, Hommes D, Bell C, Avedano L. IBD and health-related quality of life-discovering the true impact. J Crohns Colitis 2014; 8:1281-6.
6. Schirbel A, Reichert A, Roll S, et al. Impact of pain on health-related quality of life in patients with inflammatory bowel disease. World J Gastroenterol 2010; 16:3168-77.
7. D'Haens GR. Top-down therapy for IBD: Rationale and requisite evidence. Nat Rev Gastroenterol Hepatol 2010; 7:86-92.
8. Pinho SS, Reis CA. Glycosylation in cancer: Mechanisms and clinical implications. Nat Rev Cancer 2015; 15:540-55.
9. Ohtsubo K, Marth JD. Glycosylation in cellular mechanisms of health and disease. Cell 2006; 126:855-67.
10. Carvalho S, Catarino TA, Dias AM, et al. Preventing E-cadherin aberrant N-glycosylation at Asn-554 improves its critical function in gastric cancer. Oncogene 2016; 35:1619-31.
11. Carvalho S, Oliveira T, Bartels MF, et al. O-mannosylation and N-glycosylation: Two coordinated mechanisms regulating the tumour suppressor functions of E-cadherin in cancer. Oncotarget 2016; 7:65231-46.
12. Pinho SS, Carvalho S, Marcos-Pinto R, et al. Gastric cancer: Adding glycosylation to the equation. Trends Mol Med 2013; 19:664-76.
13. Pinho SS, Figueiredo J, Cabral J, et al. E-cadherin and adherensjunctions stability in gastric carcinoma: Functional implications of glycosyltransferases involving N-glycan branching biosynthesis, N-acetylglucosaminyltransferases III and V. Biochim Biophys Acta 2013; 1830:2690-700.
14. Dias AM, Dourado J, Lago P, et al. Dysregulation of T cell receptor N-glycosylation: A molecular mechanism involved in ulcerative colitis. Hum Mol Genet 2014; 23:2416-27.
15. Dias AM, Almeida CR, Reis CA, Pinho SS. Studying T cells N-glycosylation by imaging flow cytometry. Methods Mol Biol 2016; 1389: 167-76.
16. Dias AM, Correia A, Pereira MS, et al. Metabolic control of T cell immune response through glycans in inflammatory bowel disease. Proc Natl Acad Sci U S A 2018; 115:E4651-60.
17. Rudd PM, Elliott T, Cresswell P, Wilson IA, Dwek RA. Glycosylation and the immune system. Science 2001; 291:2370-6.
18. Marth JD, Grewal PK. Mammalian glycosylation in immunity. Nat Rev Immunol 2008; 8:874-87.
19. Mkhikian H, Grigorian A, Li CF, et al. Genetics and the environment converge to dysregulate N-glycosylation in multiple sclerosis. Nat Commun 2011; 2:334.
20. Harbord M, Eliakim R, Bettenworth D, et al. Third European evidencebased consensus on diagnosis and management of ulcerative colitis. Part 2: Current management. J Crohns Colitis 2017; 11:1512.
21. Coskun M, Vermeire S, Nielsen OH. Novel targeted therapies for inflammatory bowel disease. Trends Pharmacol Sci 2017; 38:127-42.
22. Danese S, Vuitton L, Peyrin-Biroulet L. Biologic agents for IBD: Practical insights. Nat Rev Gastroenterol Hepatol 2015; 12:537-45.
23. Khare V, Lang M, Dammann K, Campregher C, Lyakhovich A, Gasche C. Modulation of N-glycosylation by mesalamine facilitates membranous E-cadherin expression in colon epithelial cells. Biochem Pharmacol 2014; 87:312-20.
24. Demetriou M, Granovsky M, Quaggin S, Dennis JW. Negative regulation of T-cell activation and autoimmunity by Mgat5 N-glycosylation. Nature 2001; 409:733-9.
25. Morgan R, Gao G, Pawling J, Dennis JW, Demetriou M, Li B. N-acetylglucosaminyltransferase V [Mgat5]-mediated N-glycosylation negatively regulates Th1 cytokine production by T cells. J Immunol 2004; 173:7200-8.
26. Pereira MS, Duraes C, Catarino TA, et al. P850: Genetic variants of MGAT5 gene are associated with ulcerative colitis severity and response to therapy. J Crohns Colitis 2018; 12(Suppl 1):S546-S547.
27. Vermeire S, Van Assche G, Rutgeerts P. C-reactive protein as a marker for inflammatory bowel disease. Inflamm Bowel Dis 2004; 10:661-5.
28. Tall AR. C-reactive protein reassessed. N Engl J Med 2004; 350:1450-2.